Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA-Gemox + Thalidomide vs AspaMetDex in ENKTL
NCT02085655Phase 3Unknown
- Start
- Apr 2013
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators, Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegaspargase, gemcitabine, oxaliplatin and thalidomide in Extranodal NK/T-cell lymphoma (ENKTL) (2 arms). Primary endpoint: Efficacy Outcome Measure at 24 months. Status: unknown.
02
Drugs
pegaspargasegemcitabineoxaliplatinthalidomide
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02085655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085655.